Gina Eriksson

Mar 24, 2023 | lupus.bmj.com | David D'Cruz |Yulia Green |Anne Marie Hammer |Gina Eriksson

SafetyWhen comparing older adults and the overall population, there were no clinically relevant differences in the incidence of AEs or SAEs in the pooled safety analysis population or the incidence of SAEs in BASE (table 2). In the pooled safety analysis population, the most commonly reported SAEs in belimumab-treated older adults were nervous system disorders and vascular disorders.